Is there a role for intensive therapy in breast cancer?

Acta Oncologica, Supplement

Volumn 38, Issue 13, 1999, Pages 37-46

  Bergh, Jonas ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE; TAMOXIFEN; THIOTEPA; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; METHOTREXATE; PACLITAXEL; PTORAFUR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; TUMOR GROWTH; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FOLLOW UP; GENETIC HETEROGENEITY; HEMORRHAGIC CYSTITIS; INFECTION; KIDNEY DYSFUNCTION; LIVER VEIN OBSTRUCTION; MORTALITY; OUTCOME ASSESSMENT; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 0032730737     PISSN: 11001704     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432752     Document Type: Conference Paper

References (97)

1. 1. Frei E, Antman K, Teicher B, et al. Bone marrow autotransplantation for solid tumors-prospects. J Clin Oncol 1989; 7: 515-26.
2. 2. Frei E, III Teicher B, Cucchi C, et al. Resistance to alkylating agents: basic studies and therapeutic implications. In: Woolley P, III, Tew K, eds Mechanims of drug resistance in neoplastic cells. Bristol-Myers Cancer Symposium. San Diego: Academic Press, 1988, 69-86.
3. 3. Schabel F, Jr, Griswold D, Fr, Corbett T, et al. Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology, Pharmacol Ther 1993; 20: 283-305.
4. 4. Skipper H, Schabel F, Jr, Wilcox W. Experimental evaluation of potential anticancer agents XIII: on the criteria and kinetics associated with 'curability' of experimental leukemia, Cancer Chemother Rep 1964; 35: 1.
5. 5. Hutchison D, Schmid F. Cross-resistance and collateral sensitivity. In: Mihich E, eds. Drug-resistance and selectivity: biochemical and cellular basis. New York: Academic Press, 1973: 73-126.
6. 6. Schabel FJ, Simpson-Herren L. Some variables in experimental tumor systems which complicate interpretation of data from in vivo kinetic and pharmacologic studies with anticancer drugs. Antibiot Chemother 1978; 23: 113-27.
7. 7. Nygren P, Csoka K, Jonsson B, et al. The cytotoxic activity of taxol in primary cultures of tumour cells from patients is partly mediated by cremophor EL. Br J Cancer 1995; 71: 478-81.
8. 8. Ayash L, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
9. 9. Bergh J. Tailored chemotherapy to equal toxicity - is it possible? In: Senn H-J, Gelber R, Goldhirsch A, Thürlimann B, eds. Adjuvant therapy of primary breast cancer. Berlin, Heidelberg, New York: Springer-Verlag, 1998: 328-40.
10. 10. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introductino of an alternative. J Clin Oncol 1996; 14: 2590-611.
11. 11. Gurney H, Ackland S, Gebski V, et al. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998; 16: 2299-304.
12. 12. Sandström M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581-8.
13. 13. Ayash L, Elias A, Schwartz G, et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14: 2984-92.
14. 14. Bergh J. Dose intensity in patients with metastatic breast cancer - time for novel thoughts? Ann Oncol 1997; 8: 109-10.
15. 15. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
16. 16. Grochow L, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Int 1990; 82: 323-5.
17. 17. Hryniuk W, Frei E, III, Wright F. A single scale for comparing dose-intensity of all chemotherapy regiments in breast cancer: summation dose-intensity, J Clin Oncol 1998; 16: 3137-3147.
18. 18. EBCTCG. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
19. 19. Fossati R, Confaloniere C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomized trial involving 31 510 women. J Clin Oncol 1998; 16: 3439-60.
20. 20. Saarto T, Blomqvist C, Rissanen P, et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997; 75: 301-5.
21. 21. EORTC New Drug Development Committee. EORTC guidelines for phase I trials with single agents in adults. Eur J Cancer Clin Oncol 1985; 21: 1005-1007.
22. 22. Bergh J, Wiklund T, Erikstein B, et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast cancer patients. Ann Oncol 1998; 9: 403-11.
23. 23. Colleoni M, Pricer K, Catiglione-Gertsch M, et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 1998; 34: 1693-700.
24. b supported by autologous bone marrow strem cells versus dose escalated and tailored FEC therapy. 35th ASCO Annual Meeting. Atlanta, Georgia. Am Soc Clin Oncol 1999; 18: 2a (Abstract 3).
25. 25. Levine M, Bramwell V, Pritchard K, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-8.
26. 26. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-5.
27. 27. Budman D, Berry D, Cirrincione C, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-11.
28. 28. Fisher B, Anderson S, Wickerham D, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-69.
29. 29. Bonneterre J, Roché H, Bremond A, et al. Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients. ASCO, 17, p. 124a, Los Angeles, 1998.
30. 30. Henderson I, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequntial paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. In: Perry M, ed. 34th Annual Meeting. Los Angeles, Ca. Am Soc Clin Oncol 1998; 17: 101a, (Abstr 390A).
31. 31. Zujewski J, Nelson A, Abrams J. Much ado about not . . . enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 1998; 90: 200-9.
32. 32. Bastholt L, Dalmark M, Gjedde S, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish breast cancer cooperative group. J Clin Oncol 1996; 14: 1146-55.
33. 33. Blomqvist C, Elomaa I, Rissanen P, et al. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer. A randomized trial comparing weekly and every 4-week administration. J Clin Oncol 1993; 11: 467-73.
34. 2) in the FEC regiment significantly increases response rates. An international randomized phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 1998; 8: 155-62.
35. 35. Carmo-Pereira J, Costa F, Henriques E, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471-3.
36. 36. Ceci G, Bisagni G, Cocconi G, et al. Cisplatin and VP16 in metastatic breast carcinoma as a third-line chemotherapy: randomized study comparing low versus high dose of cisplatin. Tumori 1995; 81: 241-4.
37. 37. Ebbs S, Saunders J, Graham G, et al. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol 1989; 28: 887-92.
38. 38. Engelsman E, Klijn J, Rubens R, et al. Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC breast cancer co-operative group phase III trial (10808). Eur J Cancer 1991; 27: 966-70.
39. 39. Focan C, Andrien J, Closon M, et al. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 1993; 11: 1253-63.
40. 40. Forastiere A, Hakes T, Wittes J, et al. Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982; 5: 243-7.
41. 41. Habeshaw T, Jones P, Steward S, et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 1991; 9: 295-304.
42. 42. Hortobagyi G, Bodey G, Buzdar A, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 1987; 5: 354-64.
43. 43. Malmström P, Malmberg M, Jönsson P-E, et al. A dose intensity study of epirubicin weekly for disseminated breast cancer. Breast 1997; 6: 234.
44. 44. Nabholtz J-M, Gelman K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
45. 45. Porzsolt F, Kreuser E, Meuret G, et al. High-intensity therapy versus low-intensity therapy in advanced breast cancer patients. Cancer Treat Rev 1990; 17: 287-92.
46. 46. Richards M, Hopwood P, Ramirez A, et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer 1992; 28A: 1023-8.
47. 47. Rosner D, Nemoto T, Lane W. A randomized study of intensive verus moderate chemotherapy programs in metastatic breast cancer. Cancer 1987; 59: 874-83.
48. 48. Tannock I, Boyd N, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
49. 49. Walters R, Frye D, Buzdar A, et al. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 1992; 69: 476-81.
50. 50. Antman K, Souhami R. High-dose chemotherapy in solid tumours. Ann Oncol 1993; 4: 29-44.
51. 51. Antman K, Rowlings P, Vaughan W, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
52. 52. EMBT. In: Rosti G, Ferrante P, eds. Solid tumours working party and registry. Gruppo editoriale faenza editrice s.p.a. edizioni CELI, 1997: 41-53.
53. 53. Antman K, Ayash L. Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-10.
54. 54. Antman K, Gale R. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570-4.
55. 55. Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-9.
56. 56. Broun E, Sledge G, Einhorn L, et al. High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer. Am J Clin Oncol 1993; 16: 9-13.
57. 57. Dunphy F. Spitzer G, Budzar A, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-16.
58. 58. Dunphy F, Spitzer G, Fornoff J, et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support [published erratum appears in Cancer 1994; 74: 773]. Cancer 1994; 7: 2157-2167.
59. 59. Eder J, Elias A, Shear T, et al. A phase I-II study of cyclophosphamide, thiotepa, and carbonplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239-45.
60. 60. Fields K, Elfenbein G, Perkins J, et al. Two novel high-dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Semin Oncol 1993; 20: 59-66.
61. 61. Gisselbrecht C, Extra J, Lotz J, et al. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 1996; 18: 857-63.
62. 62. Kennedy M, Beveridge R, Rowley S, et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-6.
63. 63. Livingstone R. American Society of Clinical Oncology. Educational book, 1994: 74-79.
64. 64. Ljungman P, Björkstrand B, Fornander T. et al. High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. Bone Marrow Transpl 1998; 22: 445-8.
65. 65. Perkins J, Elfenbein G, Fields K. Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Semin Oncol 1996; 23: 42-6.
66. 66. Peters W, Jones R, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autlogous cellular supports (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc ASCO 1996; 15: 149.
67. 67. Peters W, Shpall E, Jones R, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-76.
68. 68. Rodenhuis S, Richel D, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axially lymph-node involvement. Lancet 1998; 352: 515-21.
69. 69. Shah A, Hartsell W, Chalie R, et al. Patterns of failure following bone marrow transplantation for metastatic breast cancer: the role of consolidative local therapy. Int J Radiat Oncol Biol Phys 1995; 32: 1433-8.
70. 70. Wallerstein R, Spitzer G, Dynphy F, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782-8.
71. 71. Williams S, Gilewski T, Mick R, et al. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-7.
72. 72. Bergh J. High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer-a review. Acta Oncol 1995; 34: 669-74.
73. 73. Bezwoda, WR. Primary high dose chemotherapy for metastatic breast cancer: update analysis of prognostic factors. In: Perry M, ed. Thirty-Fourth Annual Meeting. Los Angeles, CA. Am Soc Clin Oncol 17: 115a (Abst 445).
74. 74. Kennedy M. High-dose chemotherapy of breast cancer: is the question answered? J Clin Oncol 1995; 13: 2477-9.
75. 75. Bezwoda W, Dansey R, Dansey LS. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology 1989; 46: 208-11.
76. 76. Chao N, Schriber J, Frimes K, et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-5.
77. 77. Kritz A, Crown J, Motzer R, et al. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. Cancer 1993; 71: 2515-21.
78. 78. Peters W, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-19.
79. 79. Rahman Z, Frye D, Buzdar A, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-7.
80. 80. Greenberg P, Hortobagyi G, Smith T, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-205.
81. 81. Peters W, Ross M, Vredenburgh J, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
82. 82. Ayash L, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-9.
83. 83. van Dam F, Schagen S, Muller M, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-8.
84. 84. Brugger W, Bross K, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumours. Blood 1994; 83: 636-40.
85. 85. Kvalheim G. Diagnosis of minimal residual disease in bone marrow and blood in cancer patients-methods and clinical implications. Acta Oncol 1998; 37: 455-62.
86. 86. Cancelas J, Querol S, Canals C, et al. Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effects on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation. Transfusion 1998; 38: 1063-70.
87. 87. Kruger W, Gruber M, Hennings S, et al. Purging and haemopoietic progenitor cell selection by CD34+ cell separation. Bone Marrow Transplant 1998; 21: 665-71.
88. 88. Shpall E, Jones R, Bearman S, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
89. 89. Cooper B, Moss T, Ross A, et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-17.
90. 90. Choksi S, Jameson B, Korngold R. A structure-based approach to designing synthetic CD8alpha peptides that can inhibit cytotoxic T-lymphocyte responses. Nat Med 1998; 4: 309-14.
91. 91. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
92. 92. Rosenberg S, Yang J, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
93. 93. Aas T, Børresen A-L, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-4.
94. 94. Bergh J, Norberg T, Sjögren S, et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-34.
95. 95. Sjögren S, Inganäs M, Lindgren A, et al. The prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-9.
96. 96. Stål O, Stenmark Askmark M, Wingren S, et al. p53 expression and the result of adjuvant therapy of breast cancer, Acta Oncol 1995; 34: 767-770.
97. 97. Thor A, Berry D, Budman D, et al. erb-B, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60.